CHMG Stock Analysis: Chemung Financial | NASDAQ
Banks - Regional | NASDAQ, USA | Market Cap: 410m USD | 12M Return: 63.9% | US1640241014 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.00M
EPS Trend: 78.1%
Qual. Beats: 3
Rev. Trend: -21.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Chemung Financial Corporation (CHMG) is a bank holding company headquartered in Elmira, New York, operating primarily through its subsidiary, Chemung Canal Trust Company. Founded in 1833, the company has a long-standing presence in the U.S. regional banking sector and provides a comprehensive suite of banking, financing, fiduciary, and other financial services.
The companys deposit products include demand, savings, and time deposits, along with non-interest and interest-bearing checking accounts and insured money market deposits. On the lending side, it offers commercial and agricultural loans to small and mid-sized businesses, commercial and residential mortgage loans, and a variety of consumer loans such as home equity lines of credit, home equity term loans, and automobile loans.
In addition to traditional banking, Chemung Financial provides ancillary financial services, including interest rate swaps, letters of credit, employee benefit plans, insurance products, mutual fund and brokerage services, and tax preparation. The company also delivers a broad range of trust and wealth management offerings, such as guardianship, custodial, trustee, investment, pension, estate planning, and employee benefit administrative services, including acting as an agent for pension, profit-sharing, and other employee benefit trusts.
- Net interest margin compresses as Fed rate cuts pressure asset yields
- Agricultural and commercial loan portfolio faces credit quality headwinds
- Wealth management fee income grows on trust and fiduciary services expansion
| Net Income: 38.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.35 > 1.0 |
| NWC/Revenue: -1.52k% < 20% (prev -1.45k%; Δ -60.72% < -1%) |
| CFO/TA 0.02 > 3% & CFO 46.0m > Net Income 38.5m |
| Net Debt (-183.4m) to EBITDA (30.4m): -6.03 < 3 |
| Current Ratio: 0.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.84m) vs 12m ago 0.58% < -2% |
| Gross Margin: 71.29% > 18% (prev 62.19%; Δ 9.11% > 0.5%) |
| Asset Turnover: 5.09% > 50% (prev 5.09%; Δ 0.00% > 0%) |
| Interest Coverage Ratio: 0.67 > 6 (EBIT TTM 27.5m / Interest Expense TTM 41.0m) |
| A: -0.75 (Total Current Assets 333.0m - Total Current Liabilities 2.47b) / Total Assets 2.85b |
| B: 0.10 (Retained Earnings 282.2m / Total Assets 2.85b) |
| C: 0.01 (EBIT TTM 27.5m / Avg Total Assets 2.77b) |
| D: 0.11 (Book Value of Equity 273.5m / Total Liabilities 2.58b) |
| Altman-Z'' = -4.42 = D |
As of November 20, 2026, the stock is trading at USD 81.21 with a total of 32,449 shares traded. Over the past week, the price has changed by -5.23%, over one month by +1.90%, over three months by -0.10% and over the past year by +63.91%.
Current recommended Stop Loss: 78.10 (which is 3.8% or 1.6 ATR below the current price).
Chemung Financial has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CHMG.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 92.4 | 13.7% |
P/E Trailing = 10.6788
P/E Forward = 9.2937
P/S = 3.3135
P/B = 1.5
Revenue TTM = 141.3m USD
EBIT TTM = 27.5m USD
EBITDA TTM = 30.4m USD
Long Term Debt = 44.1m USD (from longTermDebt, last quarter)
Short Term Debt = 88.2m USD (from shortTermDebt, last quarter)
Debt = 147.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 9.02m
Net Debt = -183.4m USD (calculated: Debt 147.1m - CCE 330.5m)
Enterprise Value = 227.1m USD (410.5m + Debt 147.1m - CCE 330.5m)
Interest Coverage Ratio = 0.67 (Ebit TTM 27.5m / Interest Expense TTM 41.0m)
EV/FCF = 5.13x (Enterprise Value 227.1m / FCF TTM 44.3m)
FCF Yield = 19.50% (FCF TTM 44.3m / Enterprise Value 227.1m)
FCF Margin = 31.35% (FCF TTM 44.3m / Revenue TTM 141.3m)
Net Margin = 27.22% (Net Income TTM 38.5m / Revenue TTM 141.3m)
Gross Margin = 71.29% ((Revenue TTM 141.3m - Cost of Revenue TTM 40.6m) / Revenue TTM)
Gross Margin QoQ = 81.51% (prev 41.31%)
Tobins Q-Ratio = 0.08 (Enterprise Value 227.1m / Total Assets 2.85b)
Interest Expense / Debt = 27.89% (Interest Expense 41.0m / Debt 147.1m)
Taxrate = 24.05% (12.2m / 50.6m)
NOPAT = 20.9m (EBIT 27.5m * (1 - 24.05%))
Current Ratio = 0.13 (Total Current Assets 333.0m / Total Current Liabilities 2.47b)
Debt / Equity = 0.54 (Debt 147.1m / totalStockholderEquity, last quarter 273.5m)
Debt / EBITDA = -6.03 (Net Debt -183.4m / EBITDA 30.4m)
Debt / FCF = -4.14 (Net Debt -183.4m / FCF TTM 44.3m)
Total Stockholder Equity = 265.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.39% (Net Income 38.5m / Total Assets 2.85b)
RoE = 14.49% (Net Income TTM 38.5m / Total Stockholder Equity 265.4m)
RoCE = 8.89% (EBIT 27.5m / Capital Employed (Equity 265.4m + L.T.Debt 44.1m))
RoIC = 4.55% (NOPAT 20.9m / Invested Capital 459.0m)
WACC = 10.74% (E(410.5m)/V(557.6m) * Re(6.99%) + D(147.1m)/V(557.6m) * Rd(27.89%) * (1-Tc(0.24)))
Discount Rate = 6.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.11 | Cagr: 0.64%
[DCF] Terminal Value 70.65% ; FCFF base≈39.5m ; Y1≈45.3m ; Y5≈66.7m
[DCF] Fair Price = 184.3 (EV 705.6m - Net Debt -183.4m = Equity 889.0m / Shares 4.82m; r=10.74% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 78.10 | EPS CAGR: 15.81% | SUE: 4.0 | # QB: 3
Revenue Correlation: -21.28 | Revenue CAGR: -0.82% | SUE: 0.44 | # QB: 0
EPS current Quarter (2027-03-31): EPS=2.03 | Chg30d=+2.97% | Revisions=+50% | Analysts=5
EPS current Year (2026-12-31): EPS=8.42 | Chg30d=+10.62% | Revisions=+50% | GrowthEPS=+45.1% | GrowthRev=+31.9%
EPS next Year (2027-12-31): EPS=8.44 | Chg30d=+3.30% | Revisions=+50% | GrowthEPS=+0.2% | GrowthRev=+7.3%
[Analyst] Revisions Ratio: +75% (up=9, down=0)